• Home
  • NEW DAY MEDICINE
  • 3 (65) 2024
  • 55 -3 (65) 2024 - Maxsudov O.M., Musashaykhova Sh.M. - THE SIGNIFICANCE OF THE MUTATION OF THE PML-RARA GENE IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA

55 -3 (65) 2024 - Maxsudov O.M., Musashaykhova Sh.M. - THE SIGNIFICANCE OF THE MUTATION OF THE PML-RARA GENE IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA

THE SIGNIFICANCE OF THE MUTATION OF THE PML-RARA GENE IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA

Maxsudov O.M. Andijan State Medical Institute

Musashaykhova Sh.M. Andijan State Medical Institute

Boboev K.T. Republican Specialized Scientific and Practical Medical Hematology Center, Uzbekistan

Musashaykhov Х.Т. Andijan State Medical Institute

Resume

In the course of the study, the peripheral blood of 145 patients with AML who were treated with of the RSNPMC of Hematology of the Republic of Uzbekistan was used as a material for molecular genetic research. Molecular genetic studies were carried out in the Department of Molecular Medicine and Cellular Technologies of the RSNPMC of Hematology of the Republic of Uzbekistan. Molecular genetic studies were carried out in the Department of Molecular Medicine and Cellular Technologies of the RSNPMC of Hematology of the Republic of Uzbekistan. Amplification of DNA sections was carried out using polymerase chain reaction (PCR) in real time using TaqMan probes. Statistical processing of the results was performed using the standard OpenEpi V.9.2 application software package.

Keywords: acute myeloid leukemia, DNA, mutation, genetic marker PML-RARA, oncohematology.

First page

294

Last page

296

For citation: Maxsudov O.M., Musashaykhova Sh.M., Boboev K.T., Musashaykhov Х.Т. - THE SIGNIFICANCE OF THE MUTATION OF THE PML-RARA GENE IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA//New Day in Medicine 3(65)2024 294-296 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. // Cancer. 2016; 122:3821-3830
  2. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. // Leukemia. 2019; 33(2):299–312.
  3. Gupta N., Pawar R., Banerjee S, et al. Spectrum and immunophenotypic profile of acute leukemia: a tertiary center flow cytometry experience. // Mediterr J Hematol Infect Dis. 2019; 11:e2019017.
  4. Gutjahr JC, Bayer E, Yu X, Laufer JM, Hopner JP, Tesanovic S, et al. CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity. // Haematologica. 2020.
  5. Hartmann L, Dutta S, Opatz S, et al. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. // Nat Commun. 2016; 7:11733.
  6. Liao D, Wang M, Liao Y, Li J, Niu T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. // Front Pharmacol. 2019; 10:609.
  7. Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. // Invest New Drugs. 2017; 35:556‐565.
  8. Nakamura K., Smyth M.J. Targeting cancer-related inflammation in the era of immunotherapy. // Immunol. Cell Biol. 2017; 95:325–332. doi: 10.1038/icb.2016.126.
  9. Rose D, Haferlach T, Schnittger S, et al. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. // Leukemia. 2017; 31:11-17.
  10. Sallman D.A., McLemore A.F., Aldrich A.L., Komrokji R.S., McGraw K.L., Dhawan A., Geyer S., Hou H.-A., Eksioglu E.A., Sullivan A., et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. // Blood. 2020; 136:2812–2823.
  11. Zhao P, Ni M, Ma D, Fang Q, Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. // Ann Hematology. 2022 Jan; (1):119-130.

    file

    download